Favipiravir Adds Near-Equivalent Of AZ India To Glenmark's Sales

Antiviral favipiravir brings stunning gains to Glenmark, almost equal to the entire India sales of some multinationals, as demand surged amid the ferocious second of COVID-19 in the country. Such brand build-up could have taken five to seven years in pre-pandemic times, experts said.

jump in rev
Huge Spurt In Glenmark's Favipiravir Sales • Source: Alamy

It’s not everyday that a pharma brand in India that’s been on the market for under 12 months goes on to emerge as the top-selling therapy in the retail market with a significant lead over the number two ranked product.

More from India

Trump Tariffs – Indian Pharma Dodges Bullet, But Sword Still Hangs?

 
• By 

Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?

How Big Pharma Is Redefining, Scaling India GCCs Amid Tech Advances

 

Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By 

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

Mounjaro In India: Price Differential, Window Of Opportunity

 

Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?

More from Focus On Asia

Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars

 

Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.

RemeGen Fast-Tracks Potential World-First BLys/APRIL Agent For gMG In Global Phase III Trial

 

RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By 

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.